iOnctura
9 known investors
Find your way into iOnctura
369 people in our graph share verified history with the iOnctura team — schools, employers, funds. One of them is your warm intro.
John Hortonunlockedknows Catherine Pickering · together at Henley Business School (overlapped)
knows the team · via Organon
knows the team · via Merck Serono
knows the team · via University of Amsterdam
×4knows the team · via Vrije Universiteit Amsterdam (VU Amsterdam)
×2knows the team · via Henley Business School
iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer. It serves oncology patients through low-toxicity therapies aimed at extending healthspan.
Founders & leadership
CP
Catherine PickeringinCo-Founder & CEOCatherine Pickering holds a PhD in Medicinal Chemistry from the Institute of Cancer Research and an MBA from Henley Business School. Before co-founding iOnctura in 2017, she led the global oncology and immuno-oncology licensing and business development function at Merck KGaA, where she completed multiple licensing and partnership agreements.
LV
Lars van der VeeninCo-Founder & CSOLars van der Veen is a medicinal chemist with experience in pharmaceutical R&D, chemistry manufacturing and controls, and program management across small and large molecule therapies. He co-founded iOnctura, a clinical-stage oncology company developing precision oral therapeutics.
ML
Michael LahninCMO
EH
Elizabeth HoltinCBO
SS
Steven SciutoinCFO
MT
Michelle TsaiinCOO
Investors · 9
Syncona✓ verifiedLondon
Inkef✓ verifiedAmsterdam
3B Future Health FundMonaco · $12M
M VenturesLos Angeles · $10.8M
VI PartnersAltendorf · $2.2M – $4.5M
XGEN VentureMilan
Also in the syndicate · 3
EIC FundMerck VenturesSchroders Capital
Funding
SEC filings, press & company announcements$85.8M disclosed across 1 round · 2024
- $85.8MSeries BJun 2024 · 2 sources
Syncona (lead), 3B Future Health Fund, EIC Fund, Inkef Capital, M Ventures, Merck Ventures, Schroders Capital, VI Partners
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does iOnctura do?
- iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer. It serves oncology patients through low-toxicity therapies aimed at extending healthspan.
- Who founded iOnctura?
- iOnctura was founded by Catherine Pickering, Lars van der Veen.
- Who are iOnctura's investors?
- iOnctura's investors include Syncona, Inkef, 3B Future Health Fund, M Ventures, VI Partners, XGEN Venture.
- How much funding has iOnctura raised?
- iOnctura has disclosed $85.8M raised across 1 round.